GlassScriptPhysician profile
Peter Jennings King
NPI 1760656540
$1,249.45
in general payments reported to CMS, 2019-2025
15 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $22.44 · 2021: $207 · 2022: $130 · 2023: $202 · 2024: $176 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $617.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $396.21 | 2021-2023 | Inspire |
| Glaxosmithkline, LLC. | $185.10 | 2024-2025 | Nucala |
| Optinose US, INC. | $159.80 | 2022-2024 | |
| Smith+Nephew, INC. | $134.75 | 2019 | |
| Genzyme Corporation | $127.10 | 2019-2025 | |
| Stryker Corporation | $77.46 | 2019-2025 | Audion Et Dilation System |
| Neurent Medical Limited | $24.61 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Regeneron Healthcare Solutions, INC. | $24.30 | 2019 | |
| Acclarent, INC | $23.74 | 2024 | Relieva Tract |
| Intersect Ent, INC. | $22.44 | 2020 | |
| Lilly USA, LLC | $20.42 | 2025 | Zepbound |
| Shire North American Group INC | $19.81 | 2019 | |
| Alk-Abello, INC | $15.73 | 2019 | |
| Hologic Sales and Service, LLC | $12.93 | 2023 | Coolseal Generator |
| Aerin Medical INC. | $5.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.